NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws.
On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. The majority of the decline was attributed to a 17% y/y decline in Biosimilars and an 11% y/y drop in Established Brands on the loss of Atozet exclusivity. On the back of these results, OGN announced it was cutting its dividend from $0.28 to $0.02 (a decrease of more than 92%).
Following this news, the price of Organon stock fell more than 28% on the same day. To obtain additional information, go to:
https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=147208&wire=1
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original
press release on ACCESS Newswire
